Tiziana presents Phase 2a intranasal foralumab MSA trial poster at World Parkinson Congress
PUBT · 12h ago
Share
Listen to the news
- Tiziana Life Sciences flagged a late-breaking poster on its Phase 2a trial of intranasal foralumab in Multiple System Atrophy (MSA), scheduled for presentation at 7th World Parkinson Congress on May 24-27, 2026.
- Poster will outline trial design and rationale, not clinical results.
- Study tests whether intranasal foralumab can reduce neuroinflammation tied to disease progression in MSA, condition with no approved disease-modifying therapy.
- Open-label Phase 2a trial plans to enroll up to 10 patients for 6 months of dosing.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604140700OMX_____CNEWS_EN_GNW9689299_en) on April 14, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved